Your browser doesn't support javascript.
loading
ChAdOx1 nCoV-19 (AZD1222) protects against SARS-CoV-2 B.1.351 and B.1.1.7
Robert Fischer; Neeltje van Doremalen; Danielle Adney; Claude Yinda; Julia Port; Myndi Holbrook; Jonathan Schulz; Brandi Williamson; Tina Thomas; Kent Barbian; Sarah Anzick; Stacy Ricklefs; Brian Smith; Dan Long; Craig Martens; Greg Saturday; Emmie de Wit; Sarah Gilbert; Teresa Lambe; Vincent Munster.
Afiliação
  • Robert Fischer; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Neeltje van Doremalen; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Danielle Adney; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Claude Yinda; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Julia Port; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Myndi Holbrook; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Jonathan Schulz; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Brandi Williamson; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Tina Thomas; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Kent Barbian; Research Technologies Branch, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana, USA
  • Sarah Anzick; Research Technologies Branch, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana, USA
  • Stacy Ricklefs; Research Technologies Branch, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana, USA
  • Brian Smith; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Dan Long; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Craig Martens; Research Technologies Branch, Rocky Mountain Laboratories, National Institutes of Health, Hamilton, Montana, USA
  • Greg Saturday; Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Emmie de Wit; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
  • Sarah Gilbert; The Jenner Institute, University of Oxford, Oxford, UK
  • Teresa Lambe; The Jenner Institute, University of Oxford, Oxford, UK
  • Vincent Munster; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA
Preprint em En | PREPRINT-BIORXIV | ID: ppbiorxiv-435000
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals did not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus was detected in lungs of vaccinated animals. Histopathological evaluation showed extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.
Licença
cc0
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-BIORXIV Tipo de estudo: Experimental_studies / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint